Document Detail

Economic evaluation of irbesartan in combination with hydrochlorothiazide in the treatment of hypertension in Greece.
MedLine Citation:
PMID:  20411401     Owner:  NLM     Status:  In-Data-Review    
OBJECTIVES: Hypertension is a major risk factor for cardiovascular disease and a leading cause of morbidity and mortality. This study evaluates irbesartan in relation to commonly used alternative hypertension therapies losartan and valsartan given in combination with hydrochlorothiazide (HCTZ) in the general hypertensive population in Greece.
METHODS: A Markov model with eight states of health was constructed: hypertension, myocardial infarction (MI), post-MI, angina, stroke, poststroke, heart failure, and death. The model has an annual cycle and estimates mean quality-adjusted survival and treatment cost, which reflect the hypertension treatment and managing cardiovascular events. Risk functions were used to conduct extrapolations. Data on treatment effectiveness, quality of life (QOL) and epidemiology were obtained from published clinical trials and studies. The database of the main Greek National Social Insurance Institute (IKA) was analyzed to estimate the cost of events. The analysis was done from a payer perspective. All outcomes were discounted, and prices correspond to 2008.
RESULTS: The estimated patient cost per annum was stable angina <euro>2,252, unstable angina <euro>2,572, myocardial infarction <euro>2,473, post-MI <euro>1,677, stroke <euro>12,233, poststroke <euro>1,240, heart failure <euro>2,655, coronary angiography <euro>1,544, percutaneous transluminal coronary angioplasty <euro>6,511, and coronary artery bypass graft surgery <euro>11,514. For the baseline group (age 57 years, systolic blood pressure 147 mmHg, cholesterol 6.00 mmol/L, body mass index 29) of men with mild to moderate hypertension, for irbesartan, the total treatment cost was <euro>15,146, for losartan <euro>15,696 and for valsartan <euro>15,613; the quality-adjusted life years (QALYs) were irbesartan 12.67, losartan 12.63 and valsartan 12.64. For the baseline group of women with mild to moderate hypertension, the total treatment cost was <euro>12,945 for irbesartan, <euro>13,424 for losartan and <euro>13,379 for valsartan; QALYs were 14.29 for irbesartan, 14.27 for losartan and 14.27 for valsartan. For men with severe hypertension, for irbesartan and losartan, the total treatment cost was <euro>18,679 and <euro>21,488 and QALYs 12.47 and 12.37, respectively. For women, the total treatment cost was <euro>16,202 and <euro>19,099 and QALYs 14.16 and 14.09, respectively. Similar results were obtained in relation to other treatment groups in various sensitivity analysis scenarios.
CONCLUSIONS: Based on efficacy data from clinical trials and lower attainment costs in various hypertensive patient populations, irbesartan in combination with HCTZ compares favorably with losartan and valsartan in combination with HCTZ in the Greek setting.
Nikos Maniadakis; Mattias Ekman; Vasilios Fragoulakis; Vasiliki Papagiannopoulou; John Yfantopoulos
Publication Detail:
Type:  Journal Article     Date:  2010-04-22
Journal Detail:
Title:  The European journal of health economics : HEPAC : health economics in prevention and care     Volume:  12     ISSN:  1618-7601     ISO Abbreviation:  Eur J Health Econ     Publication Date:  2011 Jun 
Date Detail:
Created Date:  2011-04-18     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101134867     Medline TA:  Eur J Health Econ     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  253-61     Citation Subset:  IM    
Department of Health Services Management, National School of Public Health, 196 Alexandras Avenue, 115 22, Athens, Greece,
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Abiotrophia defectiva endophthalmitis with retinal involvement and infiltrative keratitis: case repo...
Next Document:  Biotransformation of mulberroside A from Morus alba results in enhancement of tyrosinase inhibition.